rabies immune globulin (human) (HyperRAB) Report issue

Biological Approved FDA
AACT ChEMBL DrugBank

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$116.8700 - $446.3133
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

bayrab | human polyclonal rabies immune globulin | human rabies immune globulin | human rabies immunoglobin | human rabies virus immune globulin | imogam | rabies immune globulin | rabies immune globulin human | rabies immune globulin (human) | rabies immune globulin,human | rabies immune globulin, human | rabies immunoglobulin | rabies immunoglobulins

Organizations (18)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Rabies (approved 1974)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Communicable Diseases (Phase 3)

Healthy Volunteers (Phase 3)

Mononegavirales Infections (Phase 3)

Rabies (Phase 3)

Rhabdoviridae Infections (Phase 3)

RNA Virus Infections (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue